CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Clinical trial NCT05659628 · RECRUITING

Trial details

NCT number: NCT05659628
Sponsor: Ningbo No. 1 Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma

Start date: 2022-12-01
Primary completion: 2024-12-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.